ALISO VIEJO, Calif.,
March 19, 2014 /PRNewswire/
-- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today
announced the appointment of Dr. Mark
Corrigan to the company's board of directors. Dr. Corrigan,
a seasoned life sciences executive joins Avanir's board with broad
healthcare industry experience.
Dr. Corrigan currently serves as president and chief executive
officer of Zalicus Inc. a public biopharmaceutical company, a
position he has held since January
2010. He has also served as a director of Zalicus and its
progenitor companies since December
2006. Prior to Zalicus, Dr. Corrigan served as executive
vice president, research and development at Sepracor, Inc. (now
known as Sunovion Pharmaceuticals, Inc.). Prior to joining
Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn,
a pharmaceutical company acquired by Pfizer, Inc. in 2003, most
recently as group vice president of Global Clinical Research and
Experimental Medicine. Prior to joining the pharmaceutical
industry, Dr. Corrigan spent five years in academic research at the
University of North Carolina Medical
School, focusing on psychoneuroendocrinology. Dr. Corrigan has also
been a member of the board of directors and audit committee of
Cubist Pharmaceuticals, Inc. since June
2008. Dr. Corrigan holds a B.A. and an M.D. from the
University of Virginia and subsequently
received specialty training in Psychiatry at Cornell and Maine Medical Center.
"It is a pleasure to welcome Mark to the Avanir Board,"
commented Craig Wheeler, chairman of
the board, "Mark brings many years of experience in the healthcare
sector combined with a deep knowledge of CNS research and
development together with broad experience in guiding the growth of
biopharma companies. I look forward to the insights he will
bring to our board and to working with him as Avanir pursues its
growth initiatives."
About Avanir Pharmaceuticals, Inc.
Avanir
Pharmaceuticals, Inc. is a biopharmaceutical company focused
on bringing innovative medicines to patients with central nervous
system disorders of high unmet medical need. As part of our
commitment, we have extensively invested in our pipeline and are
dedicated to advancing medicines that can substantially improve the
lives of patients and their loved ones. For more information about
Avanir, please visit www.avanir.com.
AVANIR® is a trademark or registered trademark of
Avanir Pharmaceuticals, Inc. in the
United States and other countries.
©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.
Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700
Joey Fleury, BrewLife
jfleury@brewlife.com
+1 (415) 946-1090
Logo -
http://photos.prnewswire.com/prnh/20130207/LA55901LOGO
SOURCE Avanir Pharmaceuticals, Inc.